{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T08:35:01Z","timestamp":1794731701419,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82388201"],"award-info":[{"award-number":["82388201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Adoptive transfer of chimeric antigen receptor (CAR)-modified natural killer (NK) cells represents a transformative approach that has significantly advanced clinical outcomes in patients with malignant hematological conditions. However, the efficacy of CAR-NK cells in treating solid tumors is limited by their exhaustion, impaired infiltration and poor persistence in the immunosuppressive tumor microenvironment (TME). As NK cell functional states are associated with IL-2 cascade, we engineered mesothelin-specific CAR-NK cells that secrete neoleukin-2\/15 (Neo-2\/15), an IL-2R\u03b2\u03b3 agonist, to resist immunosuppressive polarization within TME. The adoptively transferred Neo-2\/15-armored CAR-NK cells exhibited enhanced cytotoxicity, less exhaustion and longer persistence within TME, thereby having superior antitumor activity against pancreatic cancer and ovarian cancer. Mechanistically, Neo-2\/15 provided sustained and enhanced downstream IL-2 receptor signaling, which promotes the expression of c-Myc and nuclear respiratory factor 1 (NRF1) in CAR-NK cells. This upregulation was crucial for maintaining mitochondrial adaptability and metabolic resilience, ultimately leading to increased cytotoxicity and pronounced persistence of CAR-NK cells within the TME. The resistance against TME immunosuppressive polarization necessitated the upregulation of NRF1, which is essential to the augmentative effects elicited by Neo-2\/15. Overexpression of NRF1 significantly bolsters the antitumor efficacy of CAR-NK cells both in vitro and in vivo, with increased ATP production. Collectively, Neo-2\/15-expressing CAR-NK cells exerts superior antitumor effects by exhaustion-resistance and longer survival in solid tumors.<\/jats:p>","DOI":"10.1038\/s41392-025-02158-2","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:02:07Z","timestamp":1740960127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation"],"prefix":"10.1038","volume":"10","author":[{"given":"Jianhua","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2923-0729","authenticated-orcid":false,"given":"Yanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9677-7647","authenticated-orcid":false,"given":"Xuetao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2158_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/CM9.0000000000002818","volume":"137","author":"X Li","year":"2024","unstructured":"Li, X., Li, W., Xu, L. & Song, Y. Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments. Chin Med J 137, 1285\u20131302 (2024).","journal-title":"Chin Med J"},{"key":"2158_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-023-01680-5","volume":"9","author":"F Teng","year":"2024","unstructured":"Teng, F. et al. Programmable synthetic receptors: the next-generation of cell and gene therapies. Signal Transduct Target Ther 9, 7 (2024).","journal-title":"Signal Transduct Target Ther"},{"key":"2158_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","volume":"4","author":"D Li","year":"2019","unstructured":"Li, D. et al. Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther 4, 35 (2019).","journal-title":"Signal Transduct Target Ther"},{"key":"2158_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen, S., Zhu, H. & Jounaidi, Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther 9, 302 (2024).","journal-title":"Signal Transduct Target Ther"},{"key":"2158_CR5","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman, D. A. et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol 10, e191\u2013e202 (2023).","journal-title":"Lancet Haematol"},{"key":"2158_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382, 545\u2013553 (2020).","journal-title":"N Engl J Med"},{"key":"2158_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4103\/jcrt.JCRT_190_20","volume":"16","author":"C Li","year":"2020","unstructured":"Li, C., Yang, N., Li, H. & Wang, Z. Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis. J Cancer Res Ther 16, 393\u2013396 (2020).","journal-title":"J Cancer Res Ther"},{"key":"2158_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol 17, 527\u2013540 (2020).","journal-title":"Nat Rev Clin Oncol"},{"key":"2158_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature14587","volume":"524","author":"RM Perera","year":"2015","unstructured":"Perera, R. M. et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature 524, 361\u2013365 (2015).","journal-title":"Nature"},{"key":"2158_CR10","first-page":"1","volume":"149","author":"M Davern","year":"2022","unstructured":"Davern, M. et al. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy. J Cancer Res Clin Oncol 149, 1\u201319 (2022).","journal-title":"J Cancer Res Clin Oncol"},{"key":"2158_CR11","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.cell.2020.07.039","volume":"182","author":"F Bonnay","year":"2020","unstructured":"Bonnay, F. et al. Oxidative metabolism drives immortalization of neural stem cells during tumorigenesis. Cell 182, 1490\u20131507.e1419 (2020).","journal-title":"Cell"},{"key":"2158_CR12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.cmet.2021.03.023","volume":"33","author":"SM Poznanski","year":"2021","unstructured":"Poznanski, S. M. et al. Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment. Cell metab 33, 1205\u20131220.e1205 (2021).","journal-title":"Cell metab"},{"key":"2158_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau, D., Gielen, P., Kroesen, M., Wesseling, P. & Adema, G. J. The immunosuppressive tumour network: myeloid\u2010derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105\u2013115 (2013).","journal-title":"Immunology"},{"key":"2158_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer 22, 20 (2023).","journal-title":"Mol Cancer"},{"key":"2158_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 36, 346\u2013351 (2018).","journal-title":"Nat Biotechnol"},{"key":"2158_CR16","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.mam.2021.100968","volume":"80","author":"L Tomaipitinca","year":"2021","unstructured":"Tomaipitinca, L., Russo, E. & Bernardini, G. NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors. Mol Aspects Med 80, 100968 (2021).","journal-title":"Mol Aspects Med"},{"key":"2158_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.24976\/Discov.Med.202335176.41","volume":"35","author":"Y Fang","year":"2023","unstructured":"Fang, Y. et al. Development of FAP-Targeted Chimeric Antigen Receptor NK-92 Cells for Non-Small Cell Lung Cancer. Discov med 35, 405\u2013417 (2023).","journal-title":"Discov med"},{"key":"2158_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019).","journal-title":"Nature"},{"key":"2158_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Mart\u00ednez-Reyes","year":"2020","unstructured":"Mart\u00ednez-Reyes, I. & Chandel, N. S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun 11, 102 (2020).","journal-title":"Nat Commun"},{"key":"2158_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04719-2","volume":"9","author":"RM Loftus","year":"2018","unstructured":"Loftus, R. M. et al. Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. Nat Commun 9, 2341 (2018).","journal-title":"Nat Commun"},{"key":"2158_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ni.2936","volume":"15","author":"A Marcais","year":"2014","unstructured":"Marcais, A. et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol 15, 749\u2013757 (2014).","journal-title":"Nat Immunol"},{"key":"2158_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ni.2449","volume":"13","author":"AM Ring","year":"2012","unstructured":"Ring, A. M. et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 13, 1187\u20131195 (2012).","journal-title":"Nat Immunol"},{"key":"2158_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","volume":"6","author":"TA Waldmann","year":"2006","unstructured":"Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6, 595\u2013601 (2006).","journal-title":"Nat Rev Immunol"},{"key":"2158_CR24","doi-asserted-by":"publisher","first-page":"e96219","DOI":"10.1172\/jci.insight.96219","volume":"3","author":"M Felices","year":"2018","unstructured":"Felices, M. et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 3, e96219 (2018).","journal-title":"JCI Insight"},{"key":"2158_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41586-021-03861-0","volume":"597","author":"F Mo","year":"2021","unstructured":"Mo, F. et al. An engineered IL-2 partial agonist promotes CD8(+) T cell stemness. Nature 597, 544\u2013548 (2021).","journal-title":"Nature"},{"key":"2158_CR26","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.4049\/jimmunol.0901244","volume":"183","author":"X Zhu","year":"2009","unstructured":"Zhu, X. et al. Novel human interleukin-15 agonists. J Immunol 183, 3598\u20133607 (2009).","journal-title":"J Immunol"},{"key":"2158_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","volume":"565","author":"D-A Silva","year":"2019","unstructured":"Silva, D.-A. et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature 565, 186\u2013191 (2019).","journal-title":"Nature"},{"key":"2158_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200568119","volume":"119","author":"NK Wolf","year":"2022","unstructured":"Wolf, N. K. et al. Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I(+) tumors. Proc Natl Acad Sci USA 119, e2200568119 (2022).","journal-title":"Proc Natl Acad Sci USA"},{"key":"2158_CR29","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-13-0495","volume":"19","author":"R Kang","year":"2013","unstructured":"Kang, R., Zhang, Q., Zeh, H. J. 3rd, Lotze, M. T. & Tang, D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res 19, 4046\u20134057 (2013).","journal-title":"Clin Cancer Res"},{"key":"2158_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863346","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy. Front Immunol 13, 863346 (2022).","journal-title":"Front Immunol"},{"key":"2158_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41590-019-0388-z","volume":"20","author":"H Dong","year":"2019","unstructured":"Dong, H. et al. The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc. Nat Immunol 20, 865\u2013878 (2019).","journal-title":"Nat Immunol"},{"key":"2158_CR32","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-09-0889","volume":"15","author":"CV Dang","year":"2009","unstructured":"Dang, C. V., Le, A. & Gao, P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15, 6479\u20136483 (2009).","journal-title":"Clin Cancer Res"},{"key":"2158_CR33","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","volume":"81","author":"R Ma","year":"2021","unstructured":"Ma, R. et al. An Oncolytic Virus Expressing IL15\/IL15Ralpha Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. Cancer Res 81, 3635\u20133648 (2021).","journal-title":"Cancer Res"},{"key":"2158_CR34","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3389\/fimmu.2019.01414","volume":"10","author":"SM Poznanski","year":"2019","unstructured":"Poznanski, S. M. & Ashkar, A. A. What Defines NK Cell Functional Fate: Phenotype or Metabolism? Front Immunol 10, 1414 (2019).","journal-title":"Front Immunol"},{"key":"2158_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cmet.2018.06.021","volume":"28","author":"J Cong","year":"2018","unstructured":"Cong, J. et al. Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression. Cell Metab 28, 243\u2013255.e245 (2018).","journal-title":"Cell Metab"},{"key":"2158_CR36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","volume":"593","author":"BI Reinfeld","year":"2021","unstructured":"Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282\u2013288 (2021).","journal-title":"Nature"},{"key":"2158_CR37","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1172\/JCI131859","volume":"130","author":"MH Oh","year":"2020","unstructured":"Oh, M. H. et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest 130, 3865\u20133884 (2020).","journal-title":"J Clin Invest"},{"key":"2158_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-019-0106-z","volume":"19","author":"H Lemos","year":"2019","unstructured":"Lemos, H., Huang, L., Prendergast, G. C. & Mellor, A. L. Immune control by amino acid catabolism during tumorigenesis and therapy. Nat Rev Cancer 19, 162\u2013175 (2019).","journal-title":"Nat Rev Cancer"},{"key":"2158_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, eaba1624 (2022).","journal-title":"Science"},{"key":"2158_CR40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137, 624\u2013636 (2021).","journal-title":"Blood"},{"key":"2158_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","volume":"17","author":"A Van den Eynde","year":"2024","unstructured":"Van den Eynde, A. et al. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. J Hematol Oncol 17, 8 (2024).","journal-title":"J Hematol Oncol"},{"key":"2158_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6997","volume":"9","author":"L Li","year":"2023","unstructured":"Li, L. et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv 9, eadd6997 (2023).","journal-title":"Sci Adv"},{"key":"2158_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18, 85\u2013100 (2021).","journal-title":"Nat Rev Clin Oncol"},{"key":"2158_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953849","volume":"13","author":"A Valeri","year":"2022","unstructured":"Valeri, A. et al. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol 13, 953849 (2022).","journal-title":"Front Immunol"},{"key":"2158_CR45","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.jcyt.2015.07.020","volume":"17","author":"S Vasu","year":"2015","unstructured":"Vasu, S. et al. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. Cytotherapy 17, 1582\u20131593 (2015).","journal-title":"Cytotherapy"},{"key":"2158_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cbpa.2020.02.002","volume":"56","author":"A Quijano-Rubio","year":"2020","unstructured":"Quijano-Rubio, A., Ulge, U. Y., Walkey, C. D. & Silva, D. A. The advent of de novo proteins for cancer immunotherapy. Curr Opin Chem Biol 56, 119\u2013128 (2020).","journal-title":"Curr Opin Chem Biol"},{"key":"2158_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.632540","volume":"11","author":"M Guo","year":"2021","unstructured":"Guo, M. et al. Proliferation of Highly Cytotoxic Human Natural Killer Cells by OX40L Armed NK-92 With Secretory Neoleukin-2\/15 for Cancer Immunotherapy. Front Oncol 11, 632540 (2021).","journal-title":"Front Oncol"},{"key":"2158_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41421-024-00734-4","volume":"10","author":"B Cong","year":"2024","unstructured":"Cong, B. et al. Single-cell spatiotemporal analysis of the lungs reveals Slamf9(+) macrophages involved in viral clearance and inflammation resolution. Cell Discov 10, 104 (2024).","journal-title":"Cell Discov"},{"key":"2158_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41421-024-00733-5","volume":"10","author":"B Cong","year":"2024","unstructured":"Cong, B. et al. Single-cell spatiotemporal analysis reveals alveolar dendritic cell-T cell immunity hubs defending against pulmonary infection. Cell Discov 10, 103 (2024).","journal-title":"Cell Discov"},{"key":"2158_CR50","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","volume":"21","author":"Y-R Yu","year":"2020","unstructured":"Yu, Y.-R. et al. Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nat Immunol 21, 1540\u20131551 (2020).","journal-title":"Nat Immunol"},{"key":"2158_CR51","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/s41590-019-0511-1","volume":"20","author":"X Zheng","year":"2019","unstructured":"Zheng, X. et al. Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nat Immunol 20, 1656\u20131667 (2019).","journal-title":"Nat Immunol"},{"key":"2158_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm8182","volume":"7","author":"HS Hong","year":"2022","unstructured":"Hong, H. S. et al. OXPHOS promotes apoptotic resistance and cellular persistence in T(H)17 cells in the periphery and tumor microenvironment. Sci Immunol 7, eabm8182 (2022).","journal-title":"Sci Immunol"},{"key":"2158_CR53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cmet.2019.05.004","volume":"30","author":"G Civenni","year":"2019","unstructured":"Civenni, G. et al. Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer. Cell Metab 30, 303\u2013318.e306 (2019).","journal-title":"Cell Metab"},{"key":"2158_CR54","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L. & Dang, C. V. MYC, metabolism, and cancer. Cancer discov 5, 1024\u20131039 (2015).","journal-title":"Cancer discov"},{"key":"2158_CR55","doi-asserted-by":"publisher","first-page":"162.111","DOI":"10.4049\/jimmunol.204.Supp.162.11","volume":"204","author":"H Dong","year":"2020","unstructured":"Dong, H. et al. The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity and promotes natural killer cell memory by regulating c-Myc and mitochondrial respiration. J Immunol 204, 162.111\u2013162.111 (2020).","journal-title":"J Immunol"},{"key":"2158_CR56","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1136\/gutjnl-2020-321548","volume":"70","author":"L Hao","year":"2021","unstructured":"Hao, L. et al. ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1\u2013TFAM signalling in alcoholic steatohepatitis. Gut 70, 1933\u20131945 (2021).","journal-title":"Gut"},{"key":"2158_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12072-020-10022-4","volume":"14","author":"JX Mao","year":"2020","unstructured":"Mao, J. X. et al. Acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients. Hepatol Int 14, 347\u2013361 (2020).","journal-title":"Hepatol Int"},{"key":"2158_CR58","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ccell.2022.08.012","volume":"40","author":"Q Shi","year":"2022","unstructured":"Shi, Q. et al. Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance. Cancer Cell 40, 1207\u20131222.e1210 (2022).","journal-title":"Cancer Cell"},{"key":"2158_CR59","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cell.2018.02.061","volume":"173","author":"Y Han","year":"2018","unstructured":"Han, Y. et al. Tumor-induced generation of splenic erythroblast-like Ter-cells promotes tumor progression. Cell 173, 634\u2013648.e612 (2018).","journal-title":"Cell"},{"key":"2158_CR60","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/nprot.2016.097","volume":"11","author":"L Broutier","year":"2016","unstructured":"Broutier, L. et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc 11, 1724\u20131743 (2016).","journal-title":"Nat Protoc"},{"key":"2158_CR61","doi-asserted-by":"publisher","first-page":"e100928","DOI":"10.15252\/embj.2018100928","volume":"38","author":"TE Schnalzger","year":"2019","unstructured":"Schnalzger, T. E. et al. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. EMBO J 38, e100928 (2019).","journal-title":"EMBO J"},{"key":"2158_CR62","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ccell.2016.06.021","volume":"30","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils. Cancer cell 30, 243\u2013256 (2016).","journal-title":"Cancer cell"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02158-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02158-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02158-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:02:12Z","timestamp":1740960132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02158-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02158-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no potential conflict to disclose. X.C.o is one of the Associate Editors of Signal Transduction and Targeted Therapy, but he has not been involved in the process of the manuscript handling.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}